The three GLP-1 medications approved by the FDA to treat obesity include: Liraglutide (Saxenda/Victoza) Semaglutide (Wegovy/Ozempic/Rybelsus) Tirzepatide (Zepbound/Mounjaro) GLP-1 medications can lead to an average weight loss of 10% to 20% over 12-24 months when used alongside healthy diet and exercise changes
Increase dehydration risk : Both alcohol and GLP-1 medications can contribute to dehydration, especially if you experience vomiting or diarrhea
It may also support the development of newer treatments that target food cravings and reward-driven eating more effectively, rather than simply reducing appetite. They may help to treat alcohol use disorder Another new study found that oral semaglutide may reduce drinking and alcohol cravings in people with alcohol use disorder (AUD)
On this measure, average weight loss at 80 weeks was 19.0% on 4 mg, 25.9% on 9 mg and 28.3% on 12 mg, compared with 2.2% on placebo
Special storage conditions: Store well closed in a dry place at a temperature of 5-25 C and a relative humidity of up to 60%, away from heat sources and direct sunlight
DESCRIPTION DESCRIPTION Stim-free Fat Mobilizer An L-carnitine based formula designed to boost endurance and training volume, while providing an extra edge in weight management support